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Abstract 
BACKGROUND: Phenylketonuria (PKU) is a hereditary metabolic disorder and is inherited as autosomal recessive, 
so it is more likely to occur in consanguineous marriages. Early diagnosis is made by screening and timely 
treatment can prevent brain damage. 
METHODS: This was a descriptive study including all children identified with PKU in Qazvin Province, Iran, up to 
march 2017. The required information was obtained through interviews with parents and reviewing of cases. Data 
were analyzed using SPSS software. 
RESULTS: Of the 63 infected patients, 55.5% were residents of Qazvin City and the rest were residents of other cities 
in the province. Parents of 54.0% of the patients were related. 20.6% of patients had at least one patient with PKU in 
their family. The mean age that patients were diagnosed before screening was 34 months, and the statistical 
difference between the two groups was significant (P < 0.001). 52.4% of the patients were girls. The most common 
reason of referring of the patients before screening was a developmental delay. The prevalence of hyperactivity, 
seizures, and delay in walking and language were significantly different between the two groups (P <0.001). 
CONCLUSION: Early diagnosis and treatment of children with inherited metabolic diseases can prevent brain 
damage and retardation in them and reduce the financial and psychological burden of treating these children by 
maintaining their intelligence quotient (IQ). 
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Introduction1 
Phenylketonuria (PKU) is one of the most 
common disorders of amino acid metabolism 
and an important genetic disease. Elevated 
blood phenylalanine levels lead to irreversible 
brain damage. With timely diagnosis and 
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treatment, the intelligence quotient (IQ) of 
these children can be kept within the normal 
range.1,2 The incidence of PKU in whites is 
reported to be 1 in 10,000 live births. The 
highest incidence in the world was in Iran and 
neighboring countries and the lowest in Japan 
and Ashkenazi Jews.3,4 
Phenotypic variation in patients with PKU 
indicates molecular heterogeneity of different 
mutations in the phenylalanine hydroxylase 
(PAH) gene. More than 500 different pathogenic 
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gene. More than 53 different mutations have 
been identified in Iranian ethnic groups.5-7 
Based on the studies conducted, the prevalence 
ratio of this complication is one in 8000 in Iran.8 
High levels of phenylalanine in the blood 
saturate blood-brain barrier (BBB) transporters, 
leading to reduced brain uptake of major 
amino acids such as tyrosine and tryptophan 
as a result of brain damage. Few adults with 
PKU have had normal intelligence without any 
treatment. Magnetic resonance imaging (MRI) 
and histological brain studies in people with 
untreated or late-treated PKU have shown 
some degree of irreversible cortical atrophy.9,10  
The severity of hyperphenylalaninemia 
depends on the degree of enzyme deficiency. 
In complete deficiency of the phenylalanine 
hydroxylase, the level of phenylalanine in the 
blood increases to more than 20 mg/dl, which 
is called the classic form of PKU. If some 
activity of the phenylalanine hydroxylase 
enzyme remains, a milder form of the disease 
develops. In this case, the amount of 
phenylalanine in the blood is between 6 and 20 
mg/dl and it is called hyperphenylalaninemia. 
At least 2% of cases of hyperphenylalanemia 
are due to defects in the metabolism of 
tetrahydrobiopterin and other cofactors and 
are considered as malignant PKU.1 For each 
month of delay in treatment, the IQ of these 
children is reduced by 4 points, and if the 
treatment and food restriction are not fulfilled, 
by the end of the first year, the IQ of these 
children will be reduced by 50 points. For this 
reason, specific treatment or formula and 
restriction of phenylalanine in the diet should 
be started as soon as possible based on the 
type of disease.2 Numerous studies have been 
performed on cerebral damage and IQ 
reduction in patients with late-treated PKU.11,12  
For example, in a study by Morovatdar et 
al. in Khorasan, Iran to describe the 
characteristics of patients with PKU, 78.0% of 
the patients were reported to have a variety of 
developmental retardations. The best time to 
control PKU and maintain IQ in these patients 
is to start treatment and control the diet before 
the end of the first month of life.14  
The aim of this study was to evaluate the 
delay in starting treatment and controlling diet 
on brain damage in patients with PKU. 
This study was performed in Qazvin 
University of Medical Sciences, Qazvin, Iran 
with the code IR.QUMS.REC.1396.252, in order 
to compare the clinical manifestations of 
children with PKU before and after neonatal 
screening of this disease. 
Methods 
This was a descriptive study carried out on 
67 patients with PKU identified up to March 
2017 who were monitored in the Children 
Growth Research Center, Research Institute for 
Prevention of Non-Communicable Diseases, 
Qazvin University of Medical Sciences. Before 
the beginning of the PKU screening, these 
patients were diagnosed based on clinical 
findings, measurement of the blood 
phenylalanine level by the high performance 
liquid chromatography (HPLC) method, 
measurement of neopterin and urine biopterin, 
and in malignant cases by genetic testing. With 
the start of screening in the province in 2012, 
on the third to fifth day of birth, a blood 
sample was taken from the newborn on a 
paper filter to check the level of phenylalanine 
and was sent to a reference laboratory for 
testing. If the blood phenylalanine level was 4 
mg/dl or higher, the blood phenylalanine level 
was measured by HPLC and if the 
phenylalanine level was again higher than 3.4 
mg/dl, the patient was referred to the focal 
point of inherited metabolic diseases for 
further evaluation.15 
The required information including location, 
demographic characteristics, age of diagnosis, 
family history and history of PKU in the family, 
and clinical manifestations were obtained 
through interviews with parents, review of 
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Data were analyzed using the chi-square test in 
SPSS software (version 22, IBM Corporation, 
Armonk, NY, USA) considering P < 0.005 as the 
significance level. 
Results 
A total of 67 patients with PKU were registered 
in the patient management center. One of the 
patients who was kept in the Social Welfare 
Bureau died. One patient whose mother was 
from Turkey and whose father was Iranian had 
migrated to another place and the families of the 
two infected sisters were also unwilling to 
cooperate and provide information. Both girls 
had good IQs, one of the girls presented with 
lameness and was diagnosed with PKU in this 
family. Out of the 63 patients monitored in this 
center, 35 (55.5%) lived in Qazvin and the rest 
lived in other cities of the province. 38 (60.3%) 
patients were identified before the start of 
screening and the rest were diagnosed by 
screening. The mean height, weight, and head 
circumference of the patients at birth were  
49.0 ± 4.4 cm, 3010 ± 1290 g, and 33.67 ± 2.90 cm, 
respectively. The age range of the patients was 
from 15 days to 18 years and the mean age was 
5.65 ± 8.17 years. 54.0% of the patients' parents 
had relatives. In 20.6% of the patients, there was 
at least one infected person in the family. Eight 
patients had siblings or parents and five patients 
had relatives with PKU. After diagnosing PKU 
in a newborn at screening, it was determined 
that the patient's father and sister, who was in 
high school, also had PKU. One of the sick boys 
was the result of a twin pregnancy, but 
fortunately his sister was not infected. 
The mean age of diagnosis of the patients 
before screening was 33.72 ± 30.81 months. 
Only one patient was diagnosed at birth 
because his older brother had PKU. The age of 
the patients at the time of diagnosis varied 
from 7 to 120 months and there was a 
statistically significant difference between the 
two groups (P < 0.001). 32 (50.7%) patients 
were of preschool age, 16 (25.3%) attended 
regular school, and 10 (15.8%) attended special 
school. 5 (7.9%) patients were unable to study. 
The comparison in terms of education between 
the two groups showed significant a 
significant difference (P < 0.001). 
4.9%, 9.8%, 47.5%, and 37.7% of the patients 
were in the weight percentages of > 5, 5-25,  
25-50, and > 50%, respectively. In terms of 
height percentiles for age, 3.3, 24.0, 44.3, and 
17.0% were in percentages less than 5, 5-25,  
25-50, and more than 50, respectively. There 
was no significant difference between the two 
groups in terms of height and weight 
percentiles (Figure 1). 13 (50.0%) patients who 
were diagnosed through screening and  
20 (54.1%) patients who were diagnosed before 
screening were female and the difference 
between the two groups was not significant in 
terms of sexual prevalence.  
 
 
Figure 1. Comparison of height percentiles 
between the two groups 
 
The most common reason for referring 
patients to a doctor before screening was delay 
in sitting, walking, and talking. A number of 
patients have had skin rash, restlessness, and 
hyperactivity. There was a significant 
difference between the incidence of seizures, 
delay in walking, delay in speaking, and the 
prevalence of hyperactivity in the two groups 
(P < 0.001). Patients in the two groups did not 
differ significantly in the incidence of rash 
(Figure 2). The mean level of phenylalanine in 
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Figure 2. Prevalence of disorders in the two groups before and after  
phenylketonuria (PKU) screening 
 
Discussion 
In the present study, the incidence of seizures, 
gait delays, speech delays, and the prevalence 
of hyperactivity in children with PKU  
who were undiagnosed at birth were 
significantly higher than those diagnosed by 
screening timely. 
Failure to diagnose and treat inherited 
metabolic diseases can lead to severe mental 
retardation, seizures, and developmental 
delays. Additionally, timely diagnosis and 
treatment of PKU can maintain the IQ of these 
children.16,17 According to the National 
Phenylketonuria Incidence Screening Program, 
one case per 8,000 patients is estimated, with a 
wide range from one case per 3,000 to one case 
per 60,000 population.18 PKU is a common 
inherited metabolic disease and is inherited 
autosomal recessively, thus increasing the 
chances of contracting it in consanguineous 
marriages. 52.4% of our patients were girls and 
54.0% of our patients had relatives. 
The rate of consanguineous marriages in 
Iran is reported to be 38.6%.19 The prevalence 
of PKU varies by race and geographical 
location.13 The mean age of diagnosis of our 
patients before screening was 34 months. The 
symptoms of patients diagnosed before PKU 
screening were delayed walking and talking, 
seizures, restlessness, hyperactivity, skin rash, 
and urinary incontinence. Delays in diagnosis 
and treatment in untreated patients have led to 
varying degrees of mental retardation in these 
children. 20.6% of our patients had at least one 
affected person by PKU in the family. In a 
study in Mashhad, out of 78 patients with 
PKU, 49.0% were boys and the mean age of 
diagnosis was 19 months. 
80.0% of the parents were related and in 
24.0% of the cases there was a history of 
preterm delivery. Seizures, mental retardation, 
gait disturbance, spasticity, and bad smell of 
urine were observed in 36.0, 60.0, 50.0, 15.0, 
and 53.0% of the patients, respectively.  
Hypopigmentation, autism, hyperactivity, 
and skin wax were also reported in 14.0, 43.0, 
76.0, and 26.0% of the patients. 12.0% of the 
patients had a family history of PKU. Only 10.0 
% of the patients were diagnosed by screening 
and most patients were diagnosed before 
screening for clinical signs. The main reasons 
for referring patients were developmental 
delay, hypopigmentation of the skin and hair, 
seizures, bad breath, and hyperactivity, 
respectively. According to the screening, the 
incidence rate was one in 17,336 people. 8 
families had two patients and one family had 3 
patients.14 This study was different from our 
study in terms of the mean age of diagnosis, 
rate of disease in girls, and level of parental 
kinship. In a study conducted by Eshraghi et 
al. in Mazandaran, Iran, the mean age of 
patients diagnosed before screening was  
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were related to each other. In this report, the 
age of diagnosis of patients before screening 
was lower than in our study.13  
Conclusion 
Early diagnosis and treatment of children with 
inherited metabolic diseases can prevent brain 
damage and retardation in them and reduce 
the financial and psychological burden of 
treating these children by maintaining their IQ. 
Reducing consanguineous marriages is 
especially important if there is an affected 
person in the family. 
Conflict of Interests 
Authors have no conflict of interests. 
Acknowledgments 
The authors would like to appreciate all the archive 
personnel of Clinical Research Development Unit, 
Children Hospital, Qazvin University of Medical 
Sciences for their cooperation. 
References 
1. Sharman RR. Neuropsychological development in 
children with early and continuously treated 
phenylketonuria: Association with biochemical 
markers [PhD thesis]. Brisbane, Australian: 
Queensland University of Technology; 2011. 
2. Gunduz M, Arslan N, Unal O, Cakar S, Kuyum P, 
Bulbul SF. Depression and anxiety among parents of 
phenylketonuria children. Neurosciences (Riyadh) 
2015; 20(4): 350-6. 
3. Shoraka HR, Haghdoost AA, Baneshi MR, 
Bagherinezhad Z, Zolala F. Global prevalence of 
classic phenylketonuria based on Neonatal Screening 
Program Data: Systematic review and meta-analysis. 
Clin Exp Pediatr 2020; 63(2): 34-43. 
4. Zafar Mohtashami A, Lashkarara Gr, Khodadadi F, 
Motamedi N. Epidemiologic study of Phenylketonuria 
disease in Lorestan province. Yafteh 2016; 18(3):  
5-11. [In Persian]. 
5. Purevsuren J, Bolormaa B, Narantsetseg C, 
Batsolongo R, Enkhchimeg O, Bayalag M, et al. The 
first Mongolian cases of phenylketonuria in selective 
screening of inborn errors of metabolism. Mol Genet 
Metab Rep 2016; 9: 71-4. 
6. Alavinejad E, Sajedi SZ, Razipour M, Entezam M, 
Mohajer N, Setoodeh A, et al. A Novel variant in the 
PAH gene causing phenylketonuria in an Iranian 
pedigree. Avicenna J Med Biotechnol 2017; 9(3): 146-9. 
7. Binaafar S, Mahdieh N. Genetics of phenylketonuria 
in Iran: A review study. J Mazandaran Univ Med Sci 
2017; 27(147): 446-55. [In Persian]. 
8. Ganji F, Naseri H, Rostampour N, Sedighi M, 
Lotfizadeh M. Assessing the phenylketonuria 
screening program in newborns, Iran 2015-2016. 
Acta Med Iran 2018; 56(1): 49-55. 
9. Kliegman RM, Stanton BF, Geme JS, Schor NF. 
Nelson textbook of pediatrics. Philadelphia, PA: 
Elsevier Health Sciences; 2015. P. 636-40. 
10. Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, 
Merilainen MJ, et al. Systematic review and  
meta-analysis of neuropsychiatric symptoms and 
executive functioning in adults with phenylketonuria. 
Dev Neuropsychol 2016; 41(4): 245-60. 
11. Fatholahpuor A, Alimoradi S, Yousefi F, Kashefi H. 
Comparison of IQ scores between children with 
phenylketonuria and healthy children referring to 
Besat Hospital in Sanandaj between 2017 and  
2018. Sci J Kurdistan Univ Med Sci 2019; 24(5):  
12-21. [In Persian]. 
12. Grosse SD. Late-treated phenylketonuria and partial 
reversibility of intellectual impairment. Child Dev 
2010; 81(1): 200-11. 
13. Eshraghi P, Abaskhanian A, Mohammadhasani A. 
Characteristics of patients with phenylketonuria in 
Mazandaran Province, northern, Iran. Caspian  
J Intern Med 2010; 1(2): 72-4. 
14. Morovatdar N, Badiee Aval S, Hosseini Yazdi SMR, 
Norouzi F, Mina T. Epidemiology and clinical study of 
phenylketonuria (PKU) patients in Khorasan Province; 
Norteast Iran. Iran J neonatal 2015; 6(1): 18-22. 
15. Senemar S, Ganjekarimi H, Fathzadeh M, Senemar S, 
Tarami B, Bazrgar M. epidemiological and clinical 
study of phenylketonuria (PKU) disease in the national 
screening program of neonates, Fars Province, 
southern Iran. Iran J Public Health 1; 38(2): 58-64. 
16. Sutivijit Y, Banpavichit A, Wiwanitkit V. Prevalence 
of neonatal hypothyroidism and phenylketonuria in 
Southern Thailand: A 10-year report. Indian  
J Endocrinol Metab 2011; 15(2): 115-7. 
17. Pourfarzam M, Zadhoush F. Newborn screening for 
inherited metabolic disorders; news and views. J Res 
Med Sci 2013; 18(9): 801-8. 
18. Center of Non Communicable disease. Treatment and 
Education, National Guideline of Prevention and 
control of PKU patients. Tehran, Iran: Ministry of 
Health and Medical Education; 2008. p. 4-6. 
19. Mokhtari R, Bagga A. Consanguinity, genetic 
disorders and malformations in the Iranian 
population. Acta Biologica Szegediensis Acta Biol 
Szeged 2003; 47(1-4): 47-50. 
1.  
